GRANDPHARMA (00512.HK): GPN01020 Phase II enrols first patient
- GPN01020 is a Class 1.1 Chinese medicine converted from a hospital preparation used for over 20 years at a Grade 3A hospital.
- Earlier investigator-initiated trials showed good efficacy and safety in cutting migraine attack days and frequency.
NewTimeSpace News: On 10 November 2026, Grand Pharmaceutical Group Limited (stock code: 00512) said GPN01020, its Class 1 Chinese medicine for preventive treatment of migraine, has enrolled the first patient in a Phase II study in China. The randomised, double-blind, placebo-controlled, multicentre trial will enrol 180 migraine patients to assess efficacy, safety and tolerability against placebo in preventing attacks (blood stasis syndrome).
GPN01020 is a Class 1.1 Chinese medicine developed from a hospital preparation used clinically for over 20 years at a Grade 3A hospital. Earlier investigator-initiated studies showed good efficacy and safety in reducing attack days and frequency. The company called the enrolment a milestone for its ENT Chinese medicine portfolio, adding that the product is still in development and approval is uncertain.
- GRANDPHARMA (00512.HK): Innovative RDC Drug GPN01530-2 Granted FDA Fast Track Designation for Diagnosis of Solid Tumors
- Grand Pharmaceutical (00512.HK): TCM Class 1.1 Innovative Drug GPN01360 Completes First Patient Enrollment in Phase III Depression Study
- SF Intra-City (09699.HK): Expected Net Profit for First Half No Less Than RMB301 Million, Surge Over 120% YoY
